Rain Enhancement Technologies Holdco, Inc. Class A (RAIN) Dividend History

Company News

• Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

  NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share.

  GlobeNewswire Inc.
• 3 Top Penny Stocks to Buy According To Insiders In October

  Penny stocks to buy according to insiders. The post 3 Top Penny Stocks to Buy According To Insiders In October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: INTZ LXRX
• Rain Oncology And 3 Other Stocks Under $1 Insiders Are Buying

  The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Parks! America The Trade: Parks! America, Inc. (OTC: PRKA) Director Charles Kohnen acquired a total of 100,000 shares an average price of $0.40. To acquire these shares, it cost around $40,000. What’s Happening: Total revenues for the fiscal quarter ended July 2, 2023 fell to $2.85 million, from $3.64 million for the fiscal quarter ended July 3, 2022. What ...

  Benzinga

  Featured Companies: INTZ
• Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

  NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.

  GlobeNewswire Inc.
• Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  – Evaluating a number of opportunities to diversify pipeline in precision oncology –

  GlobeNewswire Inc.